Fentanyl transdermal system: market withdrawal. Exposes patients to a risk of overdose. The market withdrawal, due to a manufacturing defect, is more than welcome.
D000279:Administration, Cutaneous; D003257:Consumer Product Safety; D018795:Device Approval; D017277:Drug Approval; D016503:Drug Delivery Systems / Q000009:adverse effects* / Q000295:instrumentation; D062787:Drug Overdose; D004868:Equipment Failure; D005060:Europe; D005283:Fentanyl / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007478:Iontophoresis / Q000009:adverse effects* / Q000295:instrumentation; D008389:Marketing of Health Services; D011786:Quality Control
D005283:Fentanyl